Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Michael G.R. Beyaert |
Documentos disponibles escritos por este autor (1)
Refinar búsqueda
PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia / Michael G.R. Beyaert en European Neuropsychopharmacology, Año 2013 - Vol. 23 - No.3 (Marzo)
[artículo]
Título : PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia Tipo de documento: texto impreso Autores: Michael G.R. Beyaert, Autor ; Ritesh P. Daya, Autor ; Bailee A. Dyck, Autor Fecha de publicación: 2021 Artículo en la página: pp. 253-262 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: PAOPA, Regulación alostérica, Receptor de dopamina D2, Esquizofrenia, Anfetamina, Modelos animales Resumen: Allosteric modulators are emerging as new therapeutics for the treatment of psychiatric illnesses, such as schizophrenia. Conventional antipsychotic drugs are typically dopamine D2 receptor antagonists that compete with endogenous dopamine at the orthosteric site, and block excessive dopamine neurotransmission in the brain. Link: ./index.php?lvl=notice_display&id=27077
in European Neuropsychopharmacology > Año 2013 - Vol. 23 - No.3 (Marzo) . - pp. 253-262[artículo] PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia [texto impreso] / Michael G.R. Beyaert, Autor ; Ritesh P. Daya, Autor ; Bailee A. Dyck, Autor . - 2021 . - pp. 253-262.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in European Neuropsychopharmacology > Año 2013 - Vol. 23 - No.3 (Marzo) . - pp. 253-262
Palabras clave: PAOPA, Regulación alostérica, Receptor de dopamina D2, Esquizofrenia, Anfetamina, Modelos animales Resumen: Allosteric modulators are emerging as new therapeutics for the treatment of psychiatric illnesses, such as schizophrenia. Conventional antipsychotic drugs are typically dopamine D2 receptor antagonists that compete with endogenous dopamine at the orthosteric site, and block excessive dopamine neurotransmission in the brain. Link: ./index.php?lvl=notice_display&id=27077